T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| 1 | +$3.01B | |
| 2 | +$1.25B | |
| 3 | +$1.09B | |
| 4 |
XYZ
Block Inc
XYZ
|
+$1.06B |
| 5 |
Valero Energy
VLO
|
+$1.05B |
Top Sells
| 1 | +$3.94B | |
| 2 | +$1.84B | |
| 3 | +$1.47B | |
| 4 |
Eli Lilly
LLY
|
+$1.43B |
| 5 |
Tesla
TSLA
|
+$1.4B |
Sector Composition
| 1 | Technology | 30.49% |
| 2 | Healthcare | 13.92% |
| 3 | Financials | 12.27% |
| 4 | Consumer Discretionary | 10.96% |
| 5 | Communication Services | 9.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3076
iQIYI
IQ
$2.06B
| – | – |
-14,900
|
|
||
3077
Kinross Gold
KGC
$32.8B
| – | – |
-4,725,256
|
|
||
3078
Karyopharm Therapeutics
KPTI
$51.6M
| – | – |
-4,287
|
|
||
3079
SPDR S&P Regional Banking ETF
KRE
$4.02B
| – | – |
0
|
|
||
3080
LifeVantage
LFVN
$115M
| – | – |
-20,700
|
|
||
3081
MGP Ingredients
MGPI
$504M
| – | – |
-5,662
|
|
||
3082
Midland States Bancorp
MSBI
$350M
| – | – |
-8,228
|
|